[ad_1]
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann
ZURICH (Reuters) – The European Medicine Agency’s Committee for Medicinal Products for Human Use has recommended EU approval of Roche’s cancer immunotherapy Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer, the Basel company said on Friday.
The EMA also adopted a positive opinion of Tecentriq in combination with chemotherapy as an initial treatment for the most common form of advanced lung cancer – metastatic non-squamous non-small cell lung cancer – Roche said in a separate statement.
Reporting by Brenna Hughes Neghaiwi
[ad_2]
Source link